15261 Lack of tuberculosis reactivation in 12,319 patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis treated with secukinumab: An ad hoc analysis of pooled safety data from 28 clinical trials

Abstract

Introduction: TNFα inhibitors (TNFi) may increase the risk of tuberculosis (TB) and latent TB infection (LTBI) reactivation; however, data on the effects of newer biologic agents and TB is limited. This pooled safety analysis of patients treated with secukinumab, a human monoclonal antibody neutralizing IL-17A, reports long-term observed incidence rates of TB/LTBI in psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).